Who
Todd C. Davis
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Ligand Pharmaceuticals; Director and 10% owner, Pelthos Therapeutics; Director, Palvella Therapeutics; Director, Vaxart; Director, Biodelivery Sciences International; Director, Artes Medical.
In numbers
- Trades disclosed
- 184
- Buys
- 6
- Sells
- 11
- Bought
- $3.7M
- Sold
- $8.8M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 1 Mar 2007
- Last trade
- 30 Jun 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 6 Jul 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $21K132 at $160.71 | filing |
| 30 Jun 2026filed 6 Jul 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $21K132 at $160.71 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $986K35,445 at $27.80 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $14K503 at $28.73 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $985K35,445 at $27.80 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $14K503 at $28.73 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 2 Mar 2026filed 27 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,495 at $0.00 | filing |
| 2 Mar 2026filed 27 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,058 at $0.00 | filing |
| 2 Mar 2026filed 27 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,058 at $0.00 | filing |
| 2 Mar 2026filed 27 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,495 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $375K2,039 at $183.83 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $782K4,255 at $183.83 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $516K2,805 at $183.83 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $375K2,039 at $183.83 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $782K4,255 at $183.83 | filing |
| 15 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $516K2,805 at $183.83 | filing |
| 14 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —20,782 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.5M8,178 at $183.83 | filing |
News
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Downgraded by Zacks Research to Strong SellPTHS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Todd C. Davis; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.